RE
RICHARDSON ELECTRONICS, LTD. (RELL)·Q3 2024 Earnings Summary
Executive Summary
- Q3 FY2024 delivered sequential recovery with net sales up 18.7% to $52.4M and a return to profitability (diluted EPS $0.05), driven by a sharp rebound in Green Energy Solutions (GES) and improved gross margin to 29.5% .
- Year over year, revenue fell 25.6% and EPS declined from $0.44 to $0.05 as PMT sales to semiconductor wafer fab customers remained cyclical and down materially; management believes Q3 was the trough for semiconductor revenue and expects recovery in CY2024/CY2025 .
- Backlog slipped modestly to $147.7M (from $150.7M in Q2), with GES backlog rising to $36.8M; inventory decreased $4.0M sequentially, improving working capital; cash and investments ended at $18.9M .
- The Board declared a $0.06 per share quarterly cash dividend payable May 29, 2024; management guided to sequential sales growth and profitability improvements in Q4 FY2024, citing improving demand in semiconductor and GES markets .
- Stock reaction catalysts: continued GES order flow (ULTRA3000 modules, ULTRAUPS3000), confirmation of semi-cap recovery, and backlog growth; note investor focus on capital allocation (buybacks vs. dividends) and Board stock ownership commitments discussed on the call .
What Went Well and What Went Wrong
What Went Well
- GES rebounded sharply: sales up 342% sequentially to $11.5M on broader customer adoption of ULTRA3000; GES book-to-bill 1.07, backlog grew to $36.8M .
- Sequential profitability improvement: gross margin rose to 29.5% and operating income reached $1.0M; inventory decreased $4.0M, supporting working capital improvements .
- Management visibility improved: “We anticipate sequential sales growth in our fiscal 2024 fourth quarter, as well as further improvements in profitability,” said CEO Edward Richardson .
What Went Wrong
- YoY declines persisted: net sales down 25.6% to $52.4M, operating income down to $1.0M from $7.6M; diluted EPS fell to $0.05 from $0.44, reflecting PMT weakness tied to semiconductor wafer fab customers (-$11.5M impact) .
- Backlog eased sequentially to $147.7M (from $150.7M) on PMT and Canvys; Canvys faced customer pushouts in North America, though margin improved .
- Healthcare margins remain volatile despite YoY gross margin improvement to 41.6%; division still targeting breakeven in Q4 amid constrained component supply and program timing .
Financial Results
Consolidated Performance (Sequential comparison within FY2024)
Year-over-Year Snapshot (Q3)
Segment Breakdown (Q3 FY2024 vs. Q2 FY2024 and Q3 FY2023)
KPIs and Balance Sheet Highlights
Guidance Changes
Note: No explicit numeric ranges for revenue, margins, OpEx, OI&E, tax rate were provided; guidance is directional based on management commentary .
Earnings Call Themes & Trends
Management Commentary
- “Sales increased 18.7% sequentially, reflecting improving business conditions… Our net sales continue to reflect the cyclical nature of sales to semiconductor wafer fab customers that had an $11.5 million negative impact on sales during the quarter.” — Edward J. Richardson .
- “Without under absorption… consolidated gross margin for the fiscal 2024 third quarter would have been 31.0%.” — Robert J. Ben .
- “GES sales were up 342% sequentially… with the addition of new customers, new products, and new technology partners.” — Gregory Peloquin .
- “We anticipate sequential sales growth in our fiscal 2024 fourth quarter, as well as further improvements in profitability.” — Edward J. Richardson .
- “Our balance sheet remains strong with nearly $19 million in cash and no debt… we focus on improving profitability and producing positive operating cash flow in FY ’25.” — Edward J. Richardson .
Q&A Highlights
- Semi-cap outlook and margins: Management expects CY2025 to be a record year across Lam/TEL/AMAT ecosystems, with margins “better than our normal margins” given proprietary products like RF matches .
- GES Phase II and customer breadth: Phase II ULTRA3000 rollouts anticipated to match or exceed Phase I; shipments to over 12 new customers as budgets approved and orders placed; inventory on hand supports faster deliveries .
- Inventory monetization: Inventory quality seen as strong; ~$113M total with ~$5M reserves; intention to convert several million dollars to cash as orders release .
- Capital allocation: Multiple investors urged buybacks; management emphasized maintaining cash and positive operating cash flow before reconsidering repurchases; Board instituted $150k stock ownership requirement for outside directors .
- Ideal Power partnership: New global distribution and engineering partnership; potential multi-million revenue opportunities across inverter/industrial/charging applications and use in ULTRAUPS3000-related designs .
Estimates Context
- Wall Street consensus (S&P Global) for Q3 FY2024 EPS and revenue was unavailable due to system limits during retrieval; therefore, estimate comparisons cannot be shown. Values intended from S&P Global could not be retrieved; estimates context is based solely on company-reported results and management commentary.
- Where estimates are unavailable, consider monitoring near-term sell-side updates post-call to recalibrate revenue/EPS expectations for Q4 FY2024 and FY2025 (semi-cap recovery, GES timing) .
Key Takeaways for Investors
- Sequential momentum re-established as GES normalizes and semi-cap pressures likely trough; watch for confirmation via Q4 backlog growth and book-to-bill >1 in PMT/GES .
- Exposure to CY2025 semi-cap upcycle is material; proprietary content should support above-company-average margins once volumes normalize (potential EPS leverage) .
- GES diversification reduces cyclicality: ULTRA3000 adoption broadens; ULTRAUPS3000 and ULTRAPEM3000 could add incremental, higher-value streams in late CY2024/CY2025—track Suzlon OEM progress and Siemens UPS beta exits .
- Working capital actions are tangible: inventory drawdown, shipping from stock, and receivable conversion targeted—key for cash generation and potential reconsideration of buybacks later .
- Canvys backlog offers embedded demand despite near-term pushouts; margin improvements indicate operational discipline .
- Healthcare breakeven aspiration hinges on Siemens repaired tube ramp; monitor component constraint resolution and margin sustainability .
- Near-term trading: stock likely reacts to GES order flow and semi-cap commentary; medium-term thesis: combined semi-cap rebound plus GES scale-up supports margin recovery and EPS expansion.